RNR vs SPNT: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

RNR is the larger of the two ($14.20B market cap): the incumbent the market prices for continued execution (8.27x forward earnings, beta 0.13). SPNT is the smaller challenger ($3.08B), actually pricier on forward earnings (9.77x): more room to run, but more to prove. If you believe SPNT earns its premium (9.77x forward earnings, so the market expects more from it), SPNT fits. If you believe in paying less for profit, RNR fits at 8.27x.

RNR vs SPNT: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricRNRSPNTWhat it tells you
Market cap$14.20B$3.08BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E8.279.77Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E10.056.58Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.130.57Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range89% of range91% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.351.38How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: RNR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how RNR and SPNT affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. RNR and SPNT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined RNR and SPNT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does RenaissanceRe Holdings (RNR) do?

RenaissanceRe Holdings, founded in 1993 and headquartered in Bermuda, is a global provider of property, casualty, and specialty reinsurance, with a historical reputation built on sophisticated property-catastrophe risk modeling. The company operates two reporting segments: Property (led by catastrophe excess-of-loss cover for hurricanes, earthquakes, and other perils) and Casualty and Specialty (lines such as directors-and-officers, professional liability, credit, cyber, marine, and aviation). Through its Capital Partners unit it also manages third-party joint ventures and funds, earning management and performance fees on capital it does not have to hold on its own balance sheet.

Full RNR guide

What does SiriusPoint Ltd. (SPNT) do?

SiriusPoint was formed in 2021 when Third Point Reinsurance merged with Sirius International Insurance Group, and it now writes roughly $3.8 billion of gross premium a year across two segments, Insurance & Services and Reinsurance. The book spans about ten lines of business from four underwriting hubs, with accident and health the largest at roughly 27 percent of premium and general liability next at about 21 percent, and no other line above 10 percent. Alongside the underwriting operation sits International Medical Group, a travel and medical MGA that has been adding capability through bolt-on deals including Assist America in late 2025 and the World Nomads brand in early 2026. Headquarters are in Bermuda, staff numbers roughly 1,000, and the NYSE listing is the company's primary and only US listing.

Full SPNT guide

RNR vs SPNT: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • RNR drivers: Property-catastrophe pricing cycle; Third-party capital and fee income.
  • SPNT drivers: Specialty insurance replacing reinsurance in the mix; Underwriting margin, not premium growth.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is catastrophe volatility: a single major hurricane, earthquake, or wildfire season can turn a strong year into a loss and erode book value quickly. For SPNT, catastrophe and large-loss exposure has not disappeared, and a single heavy wind or wildfire season can erase a year of underwriting margin at a company of this size.

RNR or SPNT: which should you pick?

If the story you believe is RNR's (Property-catastrophe pricing cycle), RNR is the more direct way to own it; if it is SPNT's (Specialty insurance replacing reinsurance in the mix), SPNT is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the RNR and SPNT guides.

RNR vs SPNT: the full fundamentals

RNR. As of November 20, 2026, RNR trades at ~10 times trailing earnings and ~8.3 times forward estimates, and about 1.35 times book value, a valuation typical of catastrophe reinsurers whose earnings are lumpy and event-driven. The trailing multiple rose from ~6 times in October because the Q3 GAAP loss cut trailing net income to ~$1.5 billion, while operating EPS stayed strong; analysts expect operating EPS to fall from ~$49.69 in 2026 to ~$37.32 in 2027. Because a heavy loss year can compress earnings sharply, investors often weigh tangible book value per share growth over time rather than any single quarter's multiple.

SPNT. At about $26.74 the shares change hands near 1.3 times book value per diluted share ex-AOCI (about 1.4 times on Yahoo Finance's reported book), a modest premium for a carrier earning a mid-to-high-teens operating return. The trailing price to earnings ratio of roughly 6.6 is not a clean read, because trailing net income of about $495 million includes gains that will not recur; the forward multiple sits near 9.8 on consensus 2027 EPS of about $2.74, after about $2.82 expected for 2026. For an insurer, growth in book value per share plus capital returned is generally the more informative measure, and book value ex-AOCI rose 4 percent in the third quarter alone. The four-analyst mean target is about $30.25.

Headline figures (approximate, November 2026): RNR shows market cap ~$14.2 billion (price $351.48, November 20, 2026), revenue (ttm) ~$9.7 billion (Q3 2026 ~$1.67 billion), net income (ttm) ~$1.5 billion; Q3 2026 net loss of ~$161 million, operating eps, q3 2026 $12.71 vs ~$10.41 consensus; SPNT shows core gross premiums written (q3 2026) ~$991M, up ~13.7% YoY, revenue (ttm) ~$3.1B; Q3 2026 revenue ~$868M, up ~16.5% YoY, net income (ttm) ~$495M (includes non-recurring gains); Q3 2026 operating EPS $0.88 vs ~$0.64 expected, core combined ratio (q3 2026) ~90.1%.

The bottom line: RNR vs SPNT

RNR and SPNT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined RNR and SPNT exposure against your real portfolio. It is not an investment adviser.

Wondering how RNR or SPNT fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about RenaissanceRe Holdings

Ask Walnut's AI anything about RNR and see how it fits what you own.

FAQ

What is the difference between RNR and SPNT?

+

RenaissanceRe Holdings, founded in 1993 and headquartered in Bermuda, is a global provider of property, casualty, and specialty reinsurance, with a historical reputation built on sophisticated property-catastrophe risk modeling. SiriusPoint was formed in 2021 when Third Point Reinsurance merged with Sirius International Insurance Group, and it now writes roughly $3.8 billion of gross premium a year across two segments, Insurance & Services and Reinsurance. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is RNR or SPNT the better stock?

+

Neither is universally better. RNR is the larger incumbent; SPNT is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, RNR or SPNT?

+

On forward P/E (as of November 2026), RNR trades at 8.27x and SPNT at 9.77x, so RNR is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both RNR and SPNT?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of RNR vs SPNT?

+

RNR: The dominant risk is catastrophe volatility: a single major hurricane, earthquake, or wildfire season can turn a strong year into a loss and erode book value quickly. Reserve adequacy in longer-tail casualty and specialty lines is another risk, as adverse development would reverse the favorable reserve releases seen recently. The reinsurance pricing cycle can soften if industry capital, including alternative and insurance-linked securities capacity, floods the market and pushes rates down. Investment results are exposed to interest-rate and credit risk on a large fixed-income portfolio. Finally, integration and concentration risk from acquisitions such as Validus, plus exposure to climate-driven loss trends, add uncertainty to future results. After a ~29% gain in 2026 the shares sit just below the ~$357 mean target of the 16 analysts tracked (consensus rating hold; UBS moved to $366 from $349 on November 2, and RBC's $365 and BofA's $428 came in earlier notes), so less of the upside case is left unpriced than a low P/E suggests. The Q3 GAAP net loss, alongside a record operating quarter for the season, is a reminder that reported book value can move on items outside underwriting, and the 2027 consensus of ~$37.32 implies a ~25% decline in operating EPS as reinsurance pricing moderates. SPNT: Catastrophe and large-loss exposure has not disappeared, and a single heavy wind or wildfire season can erase a year of underwriting margin at a company of this size. Reserve development is the second exposure: the current streak of favorable releases is a strength today and a comparison problem later, since a company cannot release reserves indefinitely. Pricing across property catastrophe and much of casualty reinsurance has been drifting lower, which is precisely why premium is falling in that segment, and a longer soft market would pressure the 12 to 15 percent operating return target. Ownership is concentrated enough to matter, with entities associated with Daniel Loeb holding roughly 9.5 percent, and take-private speculation has circulated around the name before without a transaction ever being signed. The share price itself has moved: at about $26.74 on November 20, 2026 the stock sits near the top of its 52-week range of roughly $19.15 to $27.55, so less of the turnaround is left unpriced than a year ago. Analysts expect fourth-quarter EPS of about $0.58, down about 17% year over year, and 2027 EPS of about $2.74, slightly below 2026's expected $2.82. The RiverStone loss portfolio transfer still needs regulatory approval, and the capital it frees has not yet been allocated. Finally, the trailing headline earnings multiple near 6.6 times is flattered by non-recurring items including asset sales, so anyone anchoring on it is looking at a number the operating business does not repeat.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell RNR or SPNT; figures are approximate and dated (as of November 2026). Verify current data before investing.